Discover
EXEL
Exelixis, Inc.
53.96
1 x 51.49
1 x 56.77
bid
ask
-
0.45
0.83%
1 @ 04:00 PM
54.50 +0.54 (1.00%)
| Ytd | 23.11% | |
| 1y | 23.70% |
53.25
day range
54.47
33.76
52 week range
55.91
| Open | 54.34 | Prev Close | 54.41 | Low | 53.25 | High | 54.47 | Mkt Cap | 13.56B |
| Vol | 1.84M | Avg Vol | 2.68M | EPS | 3.02 | P/E | 17.87 | Forward P/E | 13.49 |
| Beta | 0.43 | Short Ratio | 13.08 | Inst. Own | 106.81% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-04 | 50-d Avg | 49.90 | 200-d Avg | 44.10 | 1yr Est | 49.50 |
EXEL News
benzinga.com
This PVH Analyst Turns Bearish; Here Are Top 3 Downgrades For Thursday
Wall Street analysts change outlook on top names, with downgrades and initiations. See analyst ratin
benzinga.com
Truist Securities Downgrades Exelixis to Hold, Raises Price Target to $54
Truist Securities analyst Gregory Renza downgrades Exelixis (NASDAQ:EXEL) from Buy to Hold and ra
benzinga.com
Citizens Maintains Market Outperform on Exelixis, Raises Price Target to $55
Citizens analyst Silvan Turkcan maintains Exelixis (NASDAQ:EXEL) with a Market Outperform and rai
benzinga.com
Exelixis Provides 'A Highly Defensive Investment Profile:' Analyst
Exelixis reported final STELLAR-303 data showing a survival trend for zanzalintinib combo in metasta
benzinga.com
Exelixis Reports Final STELLAR‑303 Analysis; Zanzalintinib In Combination With Tecentriq Showed Non‑
Exelixis, Inc. (NASDAQ:EXEL) today announced results from the final analysis of the dual primary end